Evidence map›Paper›PMID 42332767›Full record

ArticleAlzheimer's research & therapy2026

HDAC7 acts as an astrocytic mediator of Aβ pathology that directly engages IKK to drive astrocyte neurotoxicity and neurodegeneration in Alzheimer's disease.

Jinwang Ye, Yunsong Deng, Bingge Zhang, Chengjia Li, Xing Guo, Ruizhu Yue, Huali Wan, Yue Hao, Shifeng Xiao

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jinwang YeBrain Disease and Big Data Research Institute, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518060, Guangdong, China. yejinwang@szu.edu.cn.ORCID https://orcid.org/0000-0003-2119-8354
Yunsong DengBrain Disease and Big Data Research Institute, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518060, Guangdong, China.
Bingge ZhangDepartment of Pathophysiology, School of Basic Medicine, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Chengjia LiBrain Disease and Big Data Research Institute, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518060, Guangdong, China.
Xing GuoBrain Disease and Big Data Research Institute, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518060, Guangdong, China.
Ruizhu YueBrain Disease and Big Data Research Institute, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518060, Guangdong, China.
Huali WanDepartment of Laboratory Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, China.
Yue HaoSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China. yuehao@szu.edu.cn.
Shifeng XiaoBrain Disease and Big Data Research Institute, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, 518060, Guangdong, China. sxiao@szu.edu.cn.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2025A1515012551National Natural Science Foundation of China 82101493National Natural Science Foundation of China 82474227Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions 2023SHIBS0003Shenzhen Science and Technology Innovation Commission 20231121103959001Shenzhen science and technology research and development funds JCYJ20240813141825034
6 · The paper itself

Abstract

backgroundAstrocytes undergo reactive transformations in response to pathological stimuli and play a critical role in neuronal loss associated with Alzheimer's disease (AD). However, the intrinsic mechanisms through which astrocytes detect amyloid-β (Aβ) pathology and develop neurotoxic properties remain inadequately understood. The dysregulation of class IIa Histone deacetylases (HDACs) has been implicated in astrocyte dysfunction under pathological conditions. This study aims to elucidate the role of HDAC7 as an astrocytic mediator of Aβ that drives the formation of neurotoxic reactive astrocytes, and to propose HDAC7 as a potential therapeutic target for mitigating neuronal loss and cognitive deficits in AD.

methodsWe examined HDAC7 expression in APP/PS1 mice of varying ages using RT-qPCR, Western blotting, and immunostaining analysis. Astrocyte-specific HDAC7 overexpression and knockdown were achieved through adeno-associated virus (AAV) delivery (GfaABC1D promoter) in wild-type (WT) and APP/PS1 mice, followed by behavioral tests, immunostaining, RT-qPCR, and RNA-seq. Mechanistic studies were conducted using primary astrocytes derived from WT and Hdac7

resultsHDAC7 was selectively upregulated in plaque-adjacent astrocytes in APP/PS1 mice. Overexpression of HDAC7 specifically in astrocytes was sufficient to induce a neurotoxic transcriptional profile, neuronal loss, and cognitive deficits in both WT and young APP/PS1 mice. Mechanistically, upon Aβ stimulation, the upregulated HDAC7 directly interacted with and deacetylated IKKα and IKKβ, resulting in the activation of IKK, translocation of NF-κB to the nucleus, and subsequent expression of neurotoxic genes. This neurotoxic conversion was dependent on IKK activity, as IKK inhibition nullified the effects in astrocytes overexpressing HDAC7. Conversely, astrocytic HDAC7 knockdown or treatment with TMP195 attenuated IKK-NF-κB signaling, reduced the presence of neurotoxic reactive astrocytes, and rescued neurodegeneration and cognitive deficits in APP/PS1 mice.

conclusionsHDAC7 acts as an intrinsic effector within astrocytes, responding to Aβ pathology and converting astrocytes into a neurotoxic state through direct interaction with IKK. Targeting HDAC7 presents a promising strategy for astrocyte-directed therapeutic interventions in Alzheimer's disease.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAstrocytesHistone DeacetylasesI-kappa B KinaseAmyloid beta-Protein PrecursorAnimalsDisease Models, AnimalHumansMaleMiceMice, TransgenicAmyloid beta-PeptidesAmyloid beta-Protein PrecursorHDAC7 protein, humanHdac7 protein, mouseHistone DeacetylasesI-kappa B KinaseAlzheimer’s diseaseAmyloid‐βHDAC7NeurodegenerationNF-κBReactive astrocyte

Identifiers

PMID42332767
PMCPMC13540850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.